LT3902803T - Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui - Google Patents
Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymuiInfo
- Publication number
- LT3902803T LT3902803T LTEPPCT/US2019/068652T LTUS2019068652T LT3902803T LT 3902803 T LT3902803 T LT 3902803T LT US2019068652 T LTUS2019068652 T LT US2019068652T LT 3902803 T LT3902803 T LT 3902803T
- Authority
- LT
- Lithuania
- Prior art keywords
- heterobicyclic
- aza
- cancer
- treatment
- methods
- Prior art date
Links
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3902803T true LT3902803T (lt) | 2023-04-25 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2019/068652T LT3902803T (lt) | 2018-12-27 | 2019-12-27 | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US12077534B2 (lt) |
| EP (1) | EP3902803B1 (lt) |
| JP (2) | JP7418441B2 (lt) |
| KR (1) | KR20220051301A (lt) |
| CN (1) | CN113454085B (lt) |
| AR (1) | AR117544A1 (lt) |
| AU (1) | AU2019416349B2 (lt) |
| CA (1) | CA3124952A1 (lt) |
| CL (1) | CL2021001721A1 (lt) |
| CO (1) | CO2021009879A2 (lt) |
| CR (1) | CR20210410A (lt) |
| DK (1) | DK3902803T3 (lt) |
| EA (1) | EA202191801A1 (lt) |
| ES (1) | ES2942310T3 (lt) |
| FI (1) | FI3902803T3 (lt) |
| GE (1) | GEP20237519B (lt) |
| HR (1) | HRP20230161T1 (lt) |
| HU (1) | HUE061834T2 (lt) |
| IL (1) | IL284326B2 (lt) |
| JO (1) | JOP20210172A1 (lt) |
| LT (1) | LT3902803T (lt) |
| MA (1) | MA54608B1 (lt) |
| MD (1) | MD3902803T2 (lt) |
| MX (1) | MX2021007829A (lt) |
| PE (1) | PE20212090A1 (lt) |
| PH (1) | PH12021551490A1 (lt) |
| PL (1) | PL3902803T3 (lt) |
| PT (1) | PT3902803T (lt) |
| RS (1) | RS64135B1 (lt) |
| SA (1) | SA521422405B1 (lt) |
| SG (1) | SG11202106637SA (lt) |
| SI (1) | SI3902803T1 (lt) |
| SM (1) | SMT202300109T1 (lt) |
| TW (1) | TWI816962B (lt) |
| UA (1) | UA127525C2 (lt) |
| WO (1) | WO2020139991A1 (lt) |
| ZA (1) | ZA202104423B (lt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| KR20210103498A (ko) | 2018-12-10 | 2021-08-23 | 아이디어야 바이오사이언시스 인코포레이티드 | 메티오닌 아데노실트랜스퍼라제 2a 억제제로서 2-옥소퀴나졸린 유도체 |
| CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| CN115960098A (zh) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022253242A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| TW202327600A (zh) | 2021-10-20 | 2023-07-16 | 香港商英科智能有限公司 | 甲硫胺酸腺苷轉移酶２ａ（ｍａｔ２ａ）抑制劑及其用途 |
| IL313564A (en) * | 2021-12-17 | 2024-08-01 | Tango Therapeutics Inc | Crystalline form of n-(6-amino-5-methylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide, pharmaceutical compositions and methods of use thereof |
| EP4434989A1 (en) * | 2021-12-21 | 2024-09-25 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Methionine adenosyltransferase 2a heterocyclic inhibitor |
| TW202342024A (zh) * | 2022-03-11 | 2023-11-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用 |
| WO2024002024A1 (zh) | 2022-06-27 | 2024-01-04 | 石药集团中奇制药技术（石家庄）有限公司 | 三环类化合物及其用途 |
| KR20240051860A (ko) | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| WO2024183778A1 (zh) * | 2023-03-06 | 2024-09-12 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| WO2024255802A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| WO2002018380A1 (en) | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| JP4105949B2 (ja) | 2000-09-15 | 2008-06-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| US8664276B2 (en) | 2011-01-28 | 2014-03-04 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CA3034705C (en) * | 2016-08-31 | 2021-08-03 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
| UA127059C2 (uk) | 2018-03-30 | 2023-03-29 | Ле Лаборатуар Сервьє | Гетеробіциклічні інгібітори mat2a і способи використання для лікування злоякісної пухлини |
| MA54609A (fr) * | 2018-12-27 | 2022-04-06 | Les Laboratoires Servier Sas | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
| CR20210670A (es) * | 2019-05-31 | 2022-02-11 | Servier Lab | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer |
-
2019
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 US US17/418,442 patent/US12077534B2/en active Active
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 CA CA3124952A patent/CA3124952A1/en active Pending
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 PH PH1/2021/551490A patent/PH12021551490A1/en unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 SM SM20230109T patent/SMT202300109T1/it unknown
- 2019-12-27 IL IL284326A patent/IL284326B2/en unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en active Application Filing
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko active Pending
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
-
2021
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3902803T (lt) | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui | |
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| IL272948A (en) | ENPP1 inhibitors and their use for cancer treatment | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| LT3601296T (lt) | 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį | |
| IL268872A (en) | Methods and compositions for treating cancers using antisense | |
| PL3490560T3 (pl) | Niraparyb do stosowania w sposobie leczenia nowotworu prostaty | |
| EA201892287A1 (ru) | Фармацевтические комбинации для лечения рака | |
| EP3487492A4 (en) | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| IL282478A (en) | Materials and methods for treating cancer | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| IL282948A (en) | Compositions and methods for treating cancer | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| LT3319995T (lt) | Sudėtinis gydymas anti-her-2 antikūno-vaisto konjugatu ir bcl-2 inhibitoriumi | |
| LT3630112T (lt) | Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism |